このサイトは医療関係者の方々を対象に作成しています。必ずご利用規約に同意の上、ご利用ください。記事内容で取り上げた薬剤の効能・効果および用法・用量には、日本国内 で承認されている内容と異なるものが、多分に含まれていますのでご注意ください。
|
Abstract #LBA3 化学療法歴を有する進行胃癌患者におけるEverolimusの第III相試験:GRANITE-1試験 Phase 3 Trial of Everolimus in Previously Treated Patients with Advanced Gastric Cancer: GRANITE-1 Eric Van Cutsem, et al. Abstract #LBA385 標準化学療法不応の切除不能進行・再発大腸癌患者に対するRegorafenibの有用性を検討した多施設共同プラセボ対照二重盲検無作為化比較第III相試験 (CORRECT試験) Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of Regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic colorectal cancer (mCRC) who have progressed after standard therapies Axel Grothey, et al. Abstract #5/#100 AVAGAST試験の探索的検討: 疾患サブタイプ別の解析と日本および他国におけるplacebo群の比較・検討 Abstract #5 AVAGAST試験登録症例における疾患サブタイプ別の生存解析 Survival analysis according to disease subtype in AVAGAST: first-line bevacizumab or placebo plus chemotherapy in patients with advanced gastric cancer Manish A. Shah, et al. Abstract #100 AVAGAST試験の患者背景にみる地域差:日本および他国のplacebo群の探索的な比較・検討 Regional differences in patient characteristics of AVAGAST: An exploratory comparison between Japanese patients and rest of world patients in the placebo arm Tomohiro Nishina, et al. Abstract #7 Sentinel lymph node mapping for T1 esophageal cancer Hiroya Takeuchi, et al. Abstract #384 Stage II結腸癌患者の遺伝子発現プロファイルに基づく予後予測分類 (ColoPrint) の臨床的および技術的validation Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of stage II colon cancer patients Josep Tabernero, et al. Abstract #387 切除不能進行・再発大腸癌2nd-line治療例に対するPanitumumab + FOLFIRI療法とFOLFIRI療法の無作為化比較第III相試験 (20050181試験) :最終報告 Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC). Alberto F. Sobrero, et al. Abstract #438 KRAS 遺伝子型に基づく切除不能進行・再発大腸癌1st-line治療選択の医療経済評価 Pharmacoeconomic analysis for K-Ras status based decisions for first line therapy of metastatic colorectal cancer (mCRC) Cristóbal Belda-Iniesta, et al. Abstract #531 Final skin toxicity and patient-reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1st-line metastatic colorectal cancer Jean-Yves Douillard, et al. Abstract #624 Irinotecanベースの2nd-line治療を受けた切除不能進行・再発大腸癌患者における予後分類のvalidation study Validation study of a prognostic classification system in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. Kentaro Yamazaki, et al. Abstract #668 切除不能進行・再発大腸癌患者における抗EGFR抗体薬治療によるざ瘡様皮疹の治療パターンと転帰 Treatment patterns and outcomes of acneiform eruptions from anti-epidermal growth factor receptor (EGFR) therapies for metastatic colorectal cancer (MCRC). Bogdan Dascalu, et al. |